197 related articles for article (PubMed ID: 27009937)
41. Benchmarking mismatch repair testing for patients with cancer receiving immunotherapy.
Bou Farhat E; Adib E; Daou M; Naqash AR; Matulonis U; Ng K; Kwiatkowski DJ; Sholl LM; Nassar AH
Cancer Cell; 2024 Feb; 42(2):323. PubMed ID: 38350424
[No Abstract] [Full Text] [Related]
42. Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer.
Zhang CM; Lv JF; Gong L; Yu LY; Chen XP; Zhou HH; Fan L
Int J Environ Res Public Health; 2016 Sep; 13(9):. PubMed ID: 27618077
[TBL] [Abstract][Full Text] [Related]
43. Comprehensive characterization of tumor microenvironment in colorectal cancer via molecular analysis.
Wu X; Yan H; Qiu M; Qu X; Wang J; Xu S; Zheng Y; Ge M; Yan L; Liang L
Elife; 2023 Jun; 12():. PubMed ID: 37267125
[TBL] [Abstract][Full Text] [Related]
44. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.
Amodio V; Lamba S; Chilà R; Cattaneo CM; Mussolin B; Corti G; Rospo G; Berrino E; Tripodo C; Pisati F; Bartolini A; Aquilano MC; Marsoni S; Mauri G; Marchiò C; Abrignani S; Di Nicolantonio F; Germano G; Bardelli A
Cancer Cell; 2023 Jan; 41(1):196-209.e5. PubMed ID: 36584674
[TBL] [Abstract][Full Text] [Related]
45. Molecular subtyping in colorectal cancer: A bridge to personalized therapy (Review).
Wang C; Zhang H; Liu Y; Wang Y; Hu H; Wang G
Oncol Lett; 2023 Jun; 25(6):230. PubMed ID: 37153060
[TBL] [Abstract][Full Text] [Related]
46. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
Lin A; Zhang J; Luo P
Front Immunol; 2020; 11():2039. PubMed ID: 32903444
[TBL] [Abstract][Full Text] [Related]
47. Unusual Microsatellite-Instable Mixed Neuroendocrine and Non-neuroendocrine Neoplasm: A Clinicopathological Inspection and Literature Review.
Pereira D; White D; Mortellaro M; Jiang K
Cancer Control; 2023; 30():10732748231160992. PubMed ID: 36840617
[TBL] [Abstract][Full Text] [Related]
48. Development and validation of magnetic resonance imaging-based radiomics models for preoperative prediction of microsatellite instability in rectal cancer.
Zhang W; Huang Z; Zhao J; He D; Li M; Yin H; Tian S; Zhang H; Song B
Ann Transl Med; 2021 Jan; 9(2):134. PubMed ID: 33569436
[TBL] [Abstract][Full Text] [Related]
49. Differences in the molecular profile of endometrial cancers from British White and British South Asian women.
Polymeros K; Guttery DS; Hew R; Bishop R; Stannard E; Macip S; Symonds P; Moss EL
PLoS One; 2020; 15(6):e0233900. PubMed ID: 32520976
[TBL] [Abstract][Full Text] [Related]
50. Colonic Adenocarcinomas Harboring NTRK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 16 Cases and Review of the Literature.
Lasota J; Chłopek M; Lamoureux J; Christiansen J; Kowalik A; Wasąg B; Felisiak-Gołąbek A; Agaimy A; Biernat W; Canzonieri V; Centonze G; Chmielik E; Daum O; Dubová M; Dziuba I; Goertz S; Góźdź S; Guttmejer-Nasierowska A; Haglund C; Hałoń A; Hartmann A; Inaguma S; Iżycka-Świeszewska E; Kaczorowski M; Kita P; Kołos M; Kopczyński J; Michal M; Milione M; Okoń K; Pęksa R; Pyzlak M; Ristimäki A; Ryś J; Szostak B; Szpor J; Szumiło J; Teresiński L; Waloszczyk P; Wejman J; Wesołowski W; Miettinen M
Am J Surg Pathol; 2020 Feb; 44(2):162-173. PubMed ID: 31567189
[TBL] [Abstract][Full Text] [Related]
51. Systemic inflammatory response predicts oncological outcomes in patients undergoing elective surgery for mismatch repair-deficient colorectal cancer.
Climent M; Ryan ÉJ; Stakelum Á; Khaw YL; Creavin B; Lloyd A; Alhassan D; Mohan HM; Kennelly R; Sheahan K; Winter DC
Int J Colorectal Dis; 2019 Jun; 34(6):1069-1078. PubMed ID: 30993458
[TBL] [Abstract][Full Text] [Related]
52. A mismatch repair-deficient and HPV-negative anorectal squamous cell carcinoma.
Jiang K; Martens B; Meyer L; Truong K; Lauwers GY
Virchows Arch; 2019 Jun; 474(6):769-773. PubMed ID: 30729336
[TBL] [Abstract][Full Text] [Related]
53. Microsatellite instability testing and its role in the management of colorectal cancer.
Kawakami H; Zaanan A; Sinicrope FA
Curr Treat Options Oncol; 2015 Jul; 16(7):30. PubMed ID: 26031544
[TBL] [Abstract][Full Text] [Related]
54. Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients.
Zhang L; Zhao J; Yu B; Song X; Sun G; Han L; Wang L; Dong S
Cancer Genet; 2017 Dec; 218-219():51-57. PubMed ID: 29153096
[TBL] [Abstract][Full Text] [Related]
55. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
[TBL] [Abstract][Full Text] [Related]
56. [Lynch syndrome and microsatellite instability: a review].
Desselle F; Verset G; Polus M; Louis E; Van Daele D
Rev Med Liege; 2012 Dec; 67(12):638-43. PubMed ID: 23342874
[TBL] [Abstract][Full Text] [Related]
57. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL
Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937
[TBL] [Abstract][Full Text] [Related]
58. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
